EFFICACY AND SAFETY OF USING COLISTIN IN NEONATES: A SYSTEMATIC REVIEW
DOI:
https://doi.org/10.53555/nnmhs.v9i5.1680Keywords:
Carbapenem-resistant Gram-negative, Colistin, Neonates, HyponatremiaAbstract
Colistin is a cationic polypeptide antibiotic that belongs to the family of polymyxins and kills bacteria by interfering with the functioning of the bacterial cell. When given intravenously, colistin has the potential to cause a number of potentially harmful side effects, the most prevalent of which is nephrotoxicity. Recent studies have shown that patients who receive therapy with intravenous colistin run a risk of developing decreased kidney function ranging from 7.5% to 18.6% of the time. This risk is higher in patients who are older. However, it is essential to keep in mind that treatment with intravenous colistin, in the same way as treatment with other nephrotoxic drugs can result in conditions such as infection, septic shock, and the failure of several organs, it is vital to keep in mind that treatment with intravenous colistin. The bactericidal actions of colistin are demonstrated to be effective against a significant proportion of Gram-negative aerobic bacilli. It wasn't until the 1950s that it was first used in the United States, but by the 1980s, intravenous versions of the drug had been phased out due to the nephrotoxicity they caused. However, due to a rise in the incidence of illnesses caused by carbapenem-resistant Gram-negative (CRGN) bacteria and a dearth of newly developed antimicrobial drugs that are active against multidrug-resistant Gram-negative germs, the effectiveness of colistin has been called into question once again. The effectiveness of colistin in newborns might range anywhere from 50 to 98 percent. In this particular research endeavor, hyponatremia was identified as a potential adverse impact.
References
Lawn JE, Blencowe H, Kinney M V, Bianchi F, Graham WJ. Evidence to inform the future for maternal and newborn health. Best Pract Res Clin Obstet Gynaecol. 2016;36:169–83.
Gomella T, Cuningham M, Eyal F. Neonatology: Management, procedure, On-Call Problems, Disease, and Drug. New York: McGraw-Hill Education; 2020.
Way C. The Millennium Development Goals Report. New York, United Nations: 2015.
Oza S, Lawn JE, Hogan DR, Mathers C, Cousens SN. Neonatal cause-of-death estimates for the early and late neonatal periods for 194 countries: 2000–2013. Bull World Health Organ. 2014;93:19–28.
Samir S; Shams A; Stephanie S; et al. Aetiology of Neonatal Infection in South Asia (ANISA): An Initiative to Identify Appropriate Program Priorities to Save Newborns. Pediatr Infect Dis J. 2016;35-(5):6–8.
Iosifidis E, Antachopoulos C, Ioannidou M, Mitroudi M, Sdougka M, Drossou-Agakidou V, et al. Colistin administration to pediatric and neonatal patients. Eur J Pediatr. 2010;169:867–74.
Falagas ME, Vouloumanou EK, Rafailidis PI. Systemic colistin use in children without cystic fibrosis: a systematic review of the literature. Int J Antimicrob Agents. 2009;33(6):503-e1.
Jajoo M, Kumar V, Jain M, Kumari S, Manchanda V. Intravenous colistin administration in neonates. Pediatr Infect Dis J. 2011;30(3):218–21.
Alan S, Yildiz D, Erdeve O, Cakir U, Kahvecioglu D, Okulu E, et al. Efficacy and safety of intravenous colistin in preterm infants with nosocomial sepsis caused by Acinetobacter baumannii. Am J Perinatol. 2014;31(12):1079–86.
Al-Lawama M, Aljbour H, Tanash A, Badran E. Intravenous colistin in the treatment of multidrug-resistant Acinetobacter in neonates. Ann Clin Microbiol Antimicrob. 2016;15:1–4.
Serafettin Tekgunduz K, Kara M, Caner I, Demirelli Y. Safety and Efficacy of Intravenous Colistin in Neonates With Culture Proven Sepsis. Iran J Pediatr. 2015 Aug;25(4):e453.
Ilhan O, Bor M, Ozdemir SA, Akbay S, Ozer EA. Efficacy and Safety of Intravenous Colistin in Very Low Birth Weight Preterm Infants. Pediatr Drugs [Internet] 2018;20(5):475–81. Available from:
https://doi.org/10.1007/s40272-018-0301-5
Al-Mouqdad M, Eljaaly K, Abdalgader A, Al-Anazi M, Taha M, Alshaibani A, et al. Safety and efficacy of colistin and fluoroquinolone in neonatal persistent late-onset sepsis. Saudi Pharm J [Internet] 2021;29(9):1013–20. Available from: https://www.sciencedirect.com/science/article/pii/S1319016421001419
Çağan E, Baş EK, Asker HS. Use of colistin in a neonatal intensive care unit: a cohort study of 65 patients. Med Sci Monit Int Med J Exp Clin Res. 2017;23:548.
Sahbudak Bal Z, Kamit Can F, Yazici P, Berna Anil A, Duyu M, Yilmaz Ciftdogan D, et al. The evaluation of safety and efficacy of colistin use in pediatric intensive care unit: Results from two reference hospitals and review of literature. J Infect Chemother [Internet] 2018;24(5):370–5. Available from:
https://www.sciencedirect.com/science/article/pii/S1341321X17303185
Jasani B, Kannan S, Nanavati R, Gogtay NJ, Thatte U. An audit of colistin use in neonatal sepsis from a tertiary care centre of a resource-limited country. Indian J Med Res [Internet] 2016;144(3). Available from:
Karbuz A, Özdemir H, Yaman A, Kocabaş BA, Odek Ç, Güriz H, et al. The use of colistin in critically ill children in a pediatric intensive care unit. Pediatr Infect Dis J. 2014 Jan;33(1):e19-24.
Nation RL, Li J. Colistin in the 21st century. Curr Opin Infect Dis. 2009 Dec;22(6):535–43.
Tamma PD, Newland JG, Pannaraj PS, Metjian TA, Banerjee R, Gerber JS, et al. The use of intravenous colistin among children in the United States: results from a multicenter, case series. Pediatr Infect Dis J. 2013 Jan;32(1):17– 22.
Paksu MS, Paksu S, Karadag A, Sensoy G, Asilioglu N, Yildizdas D, et al. Old agent, new experience: colistin use in the paediatric Intensive Care Unit--a multicentre study. Int J Antimicrob Agents. 2012 Aug;40(2):140–4.
Tunkel AR, Hartman BJ, Kaplan SL, Kaufman BA, Roos KL, Scheld WM, et al. Practice guidelines for the management of bacterial meningitis. Clin Infect Dis an Off Publ Infect Dis Soc Am. 2004 Nov;39(9):1267–84.
Cakir U, Alan S, Zeybek C, Erdeve O, Atasay B, Yalcinkaya F, et al. Acquired bartter-like syndrome associated with colistin use in a preterm infant. Ren Fail. 2013;35(3):411–3.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Licensing
Ninety Nine Publication publishes articles under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This licensing allows for any use of the work, provided the original author(s) and source are credited, thereby facilitating the free exchange and use of research for the advancement of knowledge.
Detailed Licensing Terms
Attribution (BY): Users must give appropriate credit, provide a link to the license, and indicate if changes were made. Users may do so in any reasonable manner, but not in any way that suggests the licensor endorses them or their use.
No Additional Restrictions: Users may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
